Evaluating low molecular weight heparins within a health system: Issues and strategies

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Health organizations interested in designing an outcomes or pharmacoeconomic study on the low molecular weight heparins (LMWHs) first need to clearly define the study questions they wish to answer, which may vary based on study perspective and organizational setting. Important clinical endpoints to assess include development of pulmonary emboli, recurrent thrombosis, improvement in clinical signs and symptoms, major bleeding episodes, and length of hospitalization. Important economic endpoints to assess include drug costs, laboratory monitoring costs, administration costs, and complication costs. Results obtained from properly designed studies will assist health systems in more clearly defining the role of LMWHs within their organizations.

Original languageEnglish (US)
Pages (from-to)144-148
Number of pages5
JournalFormulary
Volume34
Issue number2
StatePublished - Feb 1999
Externally publishedYes

Fingerprint

Low Molecular Weight Heparin
Costs and Cost Analysis
Health
Organizations
Pharmaceutical Economics
Drug Costs
Embolism
Signs and Symptoms
Hospitalization
Thrombosis
Economics
Hemorrhage
Lung

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Evaluating low molecular weight heparins within a health system : Issues and strategies. / Armstrong, Edward P.

In: Formulary, Vol. 34, No. 2, 02.1999, p. 144-148.

Research output: Contribution to journalArticle

@article{992005edf696495fb879679b26dea4ca,
title = "Evaluating low molecular weight heparins within a health system: Issues and strategies",
abstract = "Health organizations interested in designing an outcomes or pharmacoeconomic study on the low molecular weight heparins (LMWHs) first need to clearly define the study questions they wish to answer, which may vary based on study perspective and organizational setting. Important clinical endpoints to assess include development of pulmonary emboli, recurrent thrombosis, improvement in clinical signs and symptoms, major bleeding episodes, and length of hospitalization. Important economic endpoints to assess include drug costs, laboratory monitoring costs, administration costs, and complication costs. Results obtained from properly designed studies will assist health systems in more clearly defining the role of LMWHs within their organizations.",
author = "Armstrong, {Edward P}",
year = "1999",
month = "2",
language = "English (US)",
volume = "34",
pages = "144--148",
journal = "Formulary",
issn = "1082-801X",
publisher = "Advanstar Communications",
number = "2",

}

TY - JOUR

T1 - Evaluating low molecular weight heparins within a health system

T2 - Issues and strategies

AU - Armstrong, Edward P

PY - 1999/2

Y1 - 1999/2

N2 - Health organizations interested in designing an outcomes or pharmacoeconomic study on the low molecular weight heparins (LMWHs) first need to clearly define the study questions they wish to answer, which may vary based on study perspective and organizational setting. Important clinical endpoints to assess include development of pulmonary emboli, recurrent thrombosis, improvement in clinical signs and symptoms, major bleeding episodes, and length of hospitalization. Important economic endpoints to assess include drug costs, laboratory monitoring costs, administration costs, and complication costs. Results obtained from properly designed studies will assist health systems in more clearly defining the role of LMWHs within their organizations.

AB - Health organizations interested in designing an outcomes or pharmacoeconomic study on the low molecular weight heparins (LMWHs) first need to clearly define the study questions they wish to answer, which may vary based on study perspective and organizational setting. Important clinical endpoints to assess include development of pulmonary emboli, recurrent thrombosis, improvement in clinical signs and symptoms, major bleeding episodes, and length of hospitalization. Important economic endpoints to assess include drug costs, laboratory monitoring costs, administration costs, and complication costs. Results obtained from properly designed studies will assist health systems in more clearly defining the role of LMWHs within their organizations.

UR - http://www.scopus.com/inward/record.url?scp=0032974339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032974339&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032974339

VL - 34

SP - 144

EP - 148

JO - Formulary

JF - Formulary

SN - 1082-801X

IS - 2

ER -